Perbandingan Ceftriaxone dan Ciprofloxacin dalam Tata Laksana  Infeksi Saluran Kemih: Tinjauan Pustaka

Maya Ganda Ratna; Sinta Nurmalasari; Meta Tri Yana; Alvina Christy Maretta; Mariani Mariani; Fiola Yonandes; Alfiya Farah Anindhita

doi:10.55606/jurrike.v5i1.8152

Authors

Maya Ganda Ratna Universitas Lampung
Sinta Nurmalasari Universitas Lampung
Meta Tri Yana Universitas Lampung
Alvina Christy Maretta Universitas Lampung
Mariani Mariani Universitas Lampung
Fiola Yonandes Universitas Lampung
Alfiya Farah Anindhita Universitas Lampung

DOI:

https://doi.org/10.55606/jurrike.v5i1.8152

Keywords:

Antibiotic Therapy, Antimicrobial Resistance, Ceftriaxone, Ciprofloxacin, Urinary Tract Infection

Abstract

Urinary tract infection (UTI) is a common bacterial infection that requires appropriate antibiotic management to prevent complications and antimicrobial resistance. Ceftriaxone and ciprofloxacin are commonly used antibiotics with different clinical indications in UTI treatment. This literature review aims to compare the role of ceftriaxone and ciprofloxacin in the management of urinary tract infections. A narrative literature review was conducted using articles published within the last ten years from PubMed, ScienceDirect, and Google Scholar databases. The review focuses on clinical effectiveness, resistance patterns, and therapeutic considerations. The findings indicate that ceftriaxone is primarily used in moderate to severe or complicated UTIs, particularly in hospitalized patients, whereas ciprofloxacin is more frequently used in uncomplicated UTIs in outpatient settings. However, increasing bacterial resistance and safety concerns limit the empirical use of ciprofloxacin. These findings emphasize the importance of rational antibiotic selection based on clinical conditions and local resistance patterns.

Downloads

Download data is not yet available.

References

Bonkat, G., Bartoletti, R., Bruyère, F., Cai, T., Geerlings, S. E., Köves, B., & Wagenlehner, F. (2023). EAU guidelines on urological infections. European Association of Urology. https://uroweb.org/guidelines/urological-infections

Butler, C. C., Francis, N., Thomas-Jones, E., Llor, C., Bongard, E., & Moore, M. (2020). Variations in presentation, management, and patient outcomes of urinary tract infection: A systematic review. The Lancet Infectious Diseases, 20(7), 761–772. https://doi.org/10.1016/S1473-3099(20)30067-2

Campbell, M., McKenzie, J. E., Sowden, A., Katikireddi, S. V., Brennan, S. E., Ellis, S., Hartmann-Boyce, J., Ryan, R., Shepperd, S., Thomas, J., Welch, V., & Thomson, H. (2020). Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline. Journal of Clinical Epidemiology, 118, 143–152. https://doi.org/10.1016/j.jclinepi.2019.11.002

Flores-Mireles, A. L., Walker, J. N., & Hultgren, S. J. (2024). Urinary tract infection. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470195/

Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2020). Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nature Reviews Microbiology, 18(5), 269–284. https://doi.org/10.1038/s41579-020-0324-0

Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., & Soper, D. E. (2021). International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: 2021 update. Clinical Infectious Diseases, 73(1), e1–e15. https://doi.org/10.1093/cid/ciab216

Gupta, K., Trautner, B., & Hooton, T. M. (2022). Urinary tract infection: Clinical practice guidelines for treatment and prevention. Clinical Infectious Diseases, 74(5), 849–857. https://doi.org/10.1093/cid/ciab100

Hooton, T. M., Gupta, K., & Matsumoto, T. (2021). Antimicrobial stewardship and the rational use of antibiotics in urinary tract infections. Nature Reviews Urology, 18(9), 541–556. https://doi.org/10.1038/s41585-021-00472-3

Kahlmeter, G., & Poulsen, H. O. (2022). Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: The ECO.SENS study revisited. Journal of Antimicrobial Chemotherapy, 77(4), 893–904. https://doi.org/10.1093/jac/dkab470

Nicolle, L. E., Gupta, K., Bradley, S. F., Colgan, R., DeMuri, G. P., Drekonja, D., Eckert, L. O., Geerlings, S. E., Köves, B., & Hooton, T. M. (2022). Clinical practice guideline for the management of urinary tract infections in adults. Clinical Infectious Diseases, 74(10), e106–e132. https://doi.org/10.1093/cid/ciac013

Pulcini, C., Beovic, B., Béraud, G., Carlet, J., Cars, O., Howard, P., Levy-Hara, G., Li, H., Nathwani, D., & Vlieghe, E. (2022). Ensuring universal access to old antibiotics: A critical but neglected priority. Clinical Microbiology and Infection, 28(3), 347–354. https://doi.org/10.1016/j.cmi.2021.09.031

Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of Business Research, 104, 333–339. https://doi.org/10.1016/j.jbusres.2019.07.039

Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021). Infectious Diseases Society of America guidance on the treatment of antimicrobial resistant Gram-negative infections. Clinical Infectious Diseases, 72(7), e169–e183. https://doi.org/10.1093/cid/ciaa1478

Wagenlehner, F. M. E., Bjerklund Johansen, T. E., Cai, T., Köves, B., & Kranz, J. (2022). Epidemiology, definition and treatment of complicated urinary tract infections. Nature Reviews Urology, 19(10), 586–600. https://doi.org/10.1038/s41585-022-00601-0

Wagenlehner, F. M. E., Naber, K. G., & Weidner, W. (2020). Treatment of complicated urinary tract infections with cephalosporins and fluoroquinolones: Comparative efficacy and clinical considerations. International Journal of Antimicrobial Agents, 56(5), 106063. https://doi.org/10.1016/j.ijantimicag.2020.106063

Wagenlehner, F. M. E., Pilatz, A., & Weidner, W. (2021). Antimicrobial therapy for urinary tract infections: Current strategies and future perspectives. International Journal of Antimicrobial Agents, 58(2), 106368. https://doi.org/10.1016/j.ijantimicag.2021.106368

World Health Organization. (2023). Global report on antimicrobial resistance surveillance 2023. World Health Organization. https://www.who.int/publications/i/item/9789240073448

Zhanel, G. G., Cheung, D., Adam, H., Zelenitsky, S., Lagacé-Wiens, P. R. S., & Rubinstein, E. (2021). Review of fluoroquinolone resistance in urinary tract infections: Implications for clinical practice. Canadian Journal of Infectious Diseases & Medical Microbiology, 2021, 8890724. https://doi.org/10.1155/2021/8890724

Zhanel, G. G., Walkty, A. J., & Karlowsky, J. A. (2021). Fluoroquinolone resistance in urinary tract infections: Mechanisms and implications. Drugs, 81(2), 159–174. https://doi.org/10.1007/s40265-020-01424-7

Zowawi, H. M., Harris, P. N. A., Roberts, T. J., Tambyah, P. A., Schembri, M. A., & Pezzani, M. D. (2021). The emerging threat of antimicrobial resistance in urinary tract infections. Nature Reviews Urology, 18(10), 570–586. https://doi.org/10.1038/s41585-021-00494-6